Found: 66
Select item for more details and to access through your institution.
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 502, doi. 10.1002/ajh.27219
- By:
- Publication type:
- Article
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1142, doi. 10.1002/ajh.26639
- By:
- Publication type:
- Article
Cell‐free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. E148, doi. 10.1002/ajh.25802
- By:
- Publication type:
- Article
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 4, p. 400, doi. 10.1002/ajh.25392
- By:
- Publication type:
- Article
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 632, doi. 10.1002/ajh.24738
- By:
- Publication type:
- Article
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 5, p. 499, doi. 10.1002/ajh.24335
- By:
- Publication type:
- Article
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 9, p. 765, doi. 10.1002/ajh.23504
- By:
- Publication type:
- Article
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 9, p. 861, doi. 10.1002/ajh.23258
- By:
- Publication type:
- Article
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 7, p. 734, doi. 10.1002/ajh.23223
- By:
- Publication type:
- Article
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 11, p. 863, doi. 10.1002/ajh.21855
- By:
- Publication type:
- Article
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 2, p. 271, doi. 10.1111/ejh.13993
- By:
- Publication type:
- Article
Rituximab-Based Treatments in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 1, p. 59
- By:
- Publication type:
- Article
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. 1, doi. 10.1038/s41598-019-39672-7
- By:
- Publication type:
- Article
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 14, p. 11829, doi. 10.3390/ijms241411829
- By:
- Publication type:
- Article
A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 23, p. 13144, doi. 10.3390/ijms222313144
- By:
- Publication type:
- Article
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
- Published in:
- Diseases, 2023, v. 11, n. 3, p. 123, doi. 10.3390/diseases11030123
- By:
- Publication type:
- Article
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 468, doi. 10.1016/j.clml.2024.03.003
- By:
- Publication type:
- Article
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. 844, doi. 10.1016/j.clml.2023.07.013
- By:
- Publication type:
- Article
P-209: High response rates with IMiD retreatment post anti-CD38 exposure in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02336-3
- By:
- Publication type:
- Article
P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S104, doi. 10.1016/S2152-2650(21)02254-0
- By:
- Publication type:
- Article
P-059: miRNA profiling of CD138+ plasma cells identifies miR-181a-5p overexpression as independent predictor of short-term progression and poor treatment outcome in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S71, doi. 10.1016/S2152-2650(21)02193-5
- By:
- Publication type:
- Article
MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S441, doi. 10.1016/S2152-2650(21)01982-0
- By:
- Publication type:
- Article
Poster: MM-408: The Assessment of Stem Cell Graft Contamination via Next-Generation Flow Cytometry Serves as a Negative Predictor for Deep Remissions Post-Autologous Stem Cell Transplantation in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S253, doi. 10.1016/S2152-2650(21)01584-6
- By:
- Publication type:
- Article
Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Screening for Gaucher disease in patients with plasma cell dyscrasias.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e327, doi. 10.1016/j.clml.2019.09.537
- By:
- Publication type:
- Article
Flow-Mediated Dilatation (FMD) and Aortic Blood Pressure May Predict Cardiovascular Adverse Events During Carfilzomib Therapy: A Prospective Study in Relapsed/Refractory Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e262, doi. 10.1016/j.clml.2019.09.433
- By:
- Publication type:
- Article
Longitudinal Evaluation of Minimal Residual Disease in Patients with Multiple Myeloma who Achieve Complete Response After First Line Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e185, doi. 10.1016/j.clml.2019.09.310
- By:
- Publication type:
- Article
Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e184, doi. 10.1016/j.clml.2019.09.309
- By:
- Publication type:
- Article
Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S331, doi. 10.1016/j.clml.2019.07.322
- By:
- Publication type:
- Article
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma who Are Treated with Bortezomib-Based Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S325, doi. 10.1016/j.clml.2019.07.310
- By:
- Publication type:
- Article
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical Characteristics and Outcomes of Oligosecretory and Non-Secretory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S237, doi. 10.1016/j.clml.2018.07.125
- By:
- Publication type:
- Article
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Outcomes of Consecutive Patients With Newly Diagnosed Myeloma Requiring Dialysis: Dialysis Independence is Associated with Rapid Myeloma Response and Predicts for Longer Survival.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e62, doi. 10.1016/j.clml.2017.03.114
- By:
- Publication type:
- Article
Oligosecretory and Non-Secretory Multiple Myeloma: Incidence, Clinical Characteristics and Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e115, doi. 10.1016/j.clml.2017.03.209
- By:
- Publication type:
- Article
Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT without Dexamethasone and Bisphosphonates: Final Analysis of a Prospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e143, doi. 10.1016/j.clml.2017.03.259
- By:
- Publication type:
- Article
Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients With AL amyloidosis Treated With Bortezomib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e65, doi. 10.1016/j.clml.2017.03.119
- By:
- Publication type:
- Article
Prior Lenalidomide Resistance and the Impact of IMiD-free Interval in Patients Treated with Pomalidomide and Dexamethasone.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e115, doi. 10.1016/j.clml.2017.03.210
- By:
- Publication type:
- Article
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Antiresorptive treatment-associated ONJ.
- Published in:
- European Journal of Cancer Care, 2017, v. 26, n. 6, p. n/a, doi. 10.1111/ecc.12787
- By:
- Publication type:
- Article
miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00988-x
- By:
- Publication type:
- Article
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 8, p. 1, doi. 10.1038/s41408-021-00530-3
- By:
- Publication type:
- Article
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00381-4
- By:
- Publication type:
- Article
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 9, p. N.PAG, doi. 10.1038/s41408-020-00360-9
- By:
- Publication type:
- Article
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma
- Published in:
- 2020
- By:
- Publication type:
- Letter
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
- Published in:
- Clinical & Experimental Medicine, 2022, v. 22, n. 2, p. 319, doi. 10.1007/s10238-021-00746-4
- By:
- Publication type:
- Article
Thrombotic and bleeding complications in patients with AL amyloidosis.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 5, p. 1816, doi. 10.1111/bjh.19331
- By:
- Publication type:
- Article
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab‐based therapy.
- Published in:
- British Journal of Haematology, 2023, v. 203, n. 3, p. 411, doi. 10.1111/bjh.19042
- By:
- Publication type:
- Article
Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 2, p. 356, doi. 10.1111/bjh.17841
- By:
- Publication type:
- Article